Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant Melanoma
June 23rd 2020Axel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.
Watch
Azacitadine Plus Pevonedistat Shows Efficacy in MDS/CMML or LB AML
June 23rd 2020Mikkael Sekeres, MD, discusses a phase 2 study of pevonedistat plus azacitidine versus azacitadine monotherapy in patients with higher-risk myelodysplastic syndromes /chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia.
Watch